NIDA Funding Strategy for Fiscal Year 2023


The National Institute on Drug Abuse (NIDA) is the lead federal agency supporting scientific research on drug use.  Our mission is to advance science on drug use and addiction and to apply that knowledge to improve individual and public health through:

  • Strategically supporting and conducting basic and clinical research on drug use, its consequences, and the underlying neurobiological, behavioral, and social mechanisms involved.
  • Promoting the effective translation, implementation, and dissemination of scientific research findings to improve the prevention and treatment of substance use disorders and enhance public awareness of addiction as a brain disorder.

Funding Strategy

Funding decisions will be based primarily on the programmatic priorities of the Institute and scientific merit of the application. NIDA continues to give additional consideration to New Investigators and especially Early Stage Investigators As well as At Risk Investigators who have prior substantial funding from NIH and, unless successful in securing a substantial research grant award in the current fiscal year, will have no substantial research grant funding in the following fiscal year.

Information regarding FY 2023 NIH Extramural Financial Operations can be found at:

NIDA has established the following funding policy for FY 2023.

Competing Awards:

NIDA may reduce competing awards from the IRG recommended levels in order to increase the number of awards issued. 

  • New and competing awards will be funded at approximately the same average cost as FY 22.
  • In general, renewal grants should not increase by more than 10% over the prior year’s award.

Non-Competing Continuations Awards:

Consistent with overall NIH policy:

  • Non-competing continuation awards for will be funded at 100% of the committed levels.
  • Future year commitments will remain unchanged.